Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Bladder & urothelial cancer, drawn from the whole corpus: 162 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
BCG supply.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Bladder preservation strategies.
Nectin-4 ADC resistance.
Background: BCG-unresponsive. Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
BCG supply remains inadequate a decade after shortages began; alternatives are unproven for BCG-naive high-risk disease.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
What to give after EV + pembrolizumab fails: platinum rechallenge, HER2 or TROP2 ADCs, and bispecific ADCs are untested in sequence.
Whether perioperative therapy's high complete response rates permit bladder preservation in MIBC.
Cystoscopic surveillance burden and cost; urine biomarkers not yet guideline-endorsed to replace cystoscopy.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Overtreatment risk with systemic immunotherapy (durvalumab + BCG) in a disease many patients survive with BCG alone.
Peripheral neuropathy and skin toxicity of enfortumab vedotin limit duration; safer Nectin-4 conjugates stalled in 2026.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Upper-tract urothelial carcinoma and variant histologies are under-represented in trials.
Only one biomarker (FGFR3) is actionable; HER2 and Nectin-4 selection remain unresolved.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 63 changes by month →When this page itself was last checked or edited.
Programme deprioritised after regulatory feedback on Duravelo-2 design
Radical cystectomy remains the oncologic gold standard; bladder-sparing options: TAR-200 (Inlexzo, 2025), N-803 + BCG (Anktiva, 2024), nadofaragene firadenovec (2022), pembrolizumab (2020); cretostimogene in registration. (NCCN 2A (intravesical options); cystectomy preferred)
Cystoscopy (white or blue light) and TURBT with muscle in the specimen; re-resection for T1; CT urography; urine cytology; surveillance cystoscopy every 3-12 months by risk. (NCCN Bladder cancer guideline)
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.